Tampere University, Faculty of Medicine and Health Technology’s Post

Precision medicine It is like a tailored suit for your health—it's about customizing treatments to fit you perfectly. Instead of a one-size-fits-all approach, precision medicine considers your unique genetic makeup, lifestyle, and environment to prescribe the most effective treatments. It's like having a personalized roadmap to better health, guiding doctors to choose the right therapies for you based on your individual characteristics. In essence, precision medicine aims to maximize effectiveness while minimizing side effects by treating you as the unique individual you are. In precision medicine, doctors use genetic testing to tailor treatments to individual patients. For instance, cancer therapies can target specific mutations for better outcomes. This approach minimizes side effects and maximizes treatment effectiveness.

Understanding Ankylosing Spondylitis (AS) Diagnosis Ankylosing spondylitis is a challenging condition characterized by inflammation in the spine and other joints, presenting symptoms like pain and stiffness. Diagnosing AS can be complex as there's no single specific test that definitively identifies the condition. Instead, physicians assess a combination of physical symptoms, medical history, imaging tests, and laboratory results. Key Diagnostic Approaches: Medical History and Physical Exam: Family history of back problems or related diseases, the nature of back pain, and the effect of exercise on pain are crucial clues. Imaging Tests: Techniques like MRI and X-ray help visualize bone and soft tissue changes, potentially indicating AS even before extensive damage occurs. Laboratory Tests: While not definitive alone, tests for inflammation markers and genetic testing for the HLA-B27 gene provide additional insights. Early and accurate diagnosis is vital for managing AS effectively, highlighting the need for a multidimensional approach to detect and treat this condition. Healthcare professionals play a critical role in identifying potential cases based on a mix of symptomatic evaluation and advanced testing. For more insights on managing AS, read this article: https://lnkd.in/d4RykFTx #AnkylosingSpondylitis #Rheumatology #HealthcareInnovation #MedicalDiagnostics

[INNOVATION UPDATE] Donanemab to Treat Early Alzheimer’s disease Toxic accumulations of amyloid-beta (Aβ) protein in the brain, often called plaques, are thought to be key contributors to Alzheimer’s disease (AD) pathology. Donanemab (Kisunla) is a monoclonal antibody designed to bind to Aβ plaques and promote their clearance from the brain, thus slowing cognitive decline. Donanemab was approved by the U.S. Food and Drug Administration to treat patients with early symptomatic AD, including mild cognitive impairment as well as the mild dementia stage of AD, who have confirmed amyloid pathology. Want to learn more about this novel therapy? View the latest Emerging Health Care Innovation Brief: Emerging Healthcare Innovation Brief Volume 2 - Issue 15 (https://hubs.la/Q02KCv540) #alzheimersdisease #earlyalzheimers #dementia #neurology#patientcare #healthcare #innovation #horizonscanning #ecri

In 2023, several research findings related to endometriosis have emerged. Some of the latest advancements include: 1. A study published in Science Translational Medicine found that endometriosis may be caused by a bacterial infection. This discovery could potentially lead to new treatments and a better understanding of the condition. 2. A global study revealed compelling evidence of a shared genetic basis for endometriosis and other types of pain seemingly unrelated to endometriosis. This finding could help researchers develop more targeted treatments for endometriosis. 3. A potential new treatment for endometriosis is being tested in a groundbreaking clinical trial involving 100 women in Edinburgh and London. The trial aims to assess whether the drug dichloroacetate helps relieve pain, which could be the first non-hormonal, non-surgical treatment for endometriosis. 4. Research has shown that pelvic floor therapy could be key to tackling endometriosis-induced pain. A 2021 study showed that incorporating pelvic floor therapy as part of a lifestyle could help women with deeply infiltrative endometriosis (DIE) – a type of endometriosis that can invade the pelvic cavity. These findings contribute to the ongoing research and development of new treatments and interventions for managing endometriosis, a condition that affects around 190 million women and girls globally. #EndometriosisAwareness #EndoWarrior #EndoStrong #EndoCommunity #EndoSupport #EndoSisters #EndoAdvocate #EndoLife #EndoAware #EndoFighter #EndoPain #EndoAwarenessMonth #EndoResearch #EndoHealth #EndoAwarenessCampaign

𝗜𝗡𝗧𝗘𝗚𝗥𝗔𝗧𝗘𝗗 & 𝗛𝗢𝗟𝗜𝗦𝗧𝗜𝗖 𝗧𝗥𝗘𝗔𝗧𝗠𝗘𝗡𝗧 𝗙𝗢𝗥 𝗣𝗢𝗦𝗧-𝗖𝗢𝗩𝗜𝗗 𝗦𝗬𝗡𝗗𝗥𝗢𝗠𝗘 - 𝗜𝗩 𝗖𝗵𝗲𝗹𝗮𝘁𝗶𝗼𝗻 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗪𝗵𝗮𝘁 𝗶𝘁 𝗶𝘀: Specially formulated compound (called ‘chelator agent’) that is infused into the blood-stream of the patient intravenously. This chelator agent binds to toxic heavy metals like mercury, lead, etc. that are in various organs and tissues. The chelator agent & its concentration is chosen based on the patient’s body condition. 𝗨𝘀𝗲𝗱 𝗳𝗼𝗿: — Detoxification of Heavy-metals. — Detoxification of Inorganic toxins. 𝗘𝗳𝗳𝗲𝗰𝘁𝘀: — Reduction of systemic oxidative stress. — Reduction of systemic inflammation. — Prevents further cellular damage and mytochondrial dysfunction, in organs damaged by Covid-19. — Prevention of heavy-metal induced DNA mutations — Prevention hindrances to epigenetic mechanisms, and thereby prevent changes in gene expression. — Prevention of calcification and damage in tissue matrices. — Improvement in function of all organs and glands negatively effected by heavy metal toxicity. — Cumulative effect with other integrated therapies, is inducement of optimal immune function and healing, repair and rejuvenation of cells in all diseased organs, and thereby towards the resolution of Post-Covid Syndrome. 𝗛𝗼𝘄 𝗶𝘁'𝘀 𝗮𝗱𝗺𝗶𝗻𝗶𝘀𝘁𝗲𝗿𝗲𝗱: Intravenously, in the clinic. 𝗣𝗟𝗘𝗔𝗦𝗘 𝗥𝗘𝗔𝗗 𝗧𝗛𝗘 𝗟𝗘𝗦𝗦𝗢𝗡 𝗛𝗘𝗥𝗘 > https://lnkd.in/gAKqm2Hy — Dr Lee Cheng Lok Medical Director, Heal Within® ——————————————————————————- Disclaimer: The information in this article is intended for educational purposes only and does not replace professional medical advice. Always consult with a healthcare provider for any questions regarding a medical condition. #PostCovidSyndrome #Covid19Aftermath #LongCovid #CovidRecovery #HealthAwareness #CovidComplications #PostCovidCare #Covid19Insights #HealthEducation #CovidResearch #drlee #healwithin #healwithinmalaysia

"Mitochondrial dysfunction in heart failure: Pathophysiology, diagnostic markers, and therapeutic strategies" This review paper explores how mitochondrial dysfunction contributes to heart failure, focusing on three main areas: Pathophysiology: Energy Production: Mitochondrial dysfunction impairs ATP production, crucial for cardiac muscle contraction and function. Oxidative Stress: Dysfunctional mitochondria increase reactive oxygen species (ROS) generation, leading to oxidative damage and further heart failure progression. Cellular Apoptosis: Mitochondrial problems can trigger apoptosis (programmed cell death) in cardiac cells, which accelerates heart failure. Diagnostic Markers: The paper identifies various biomarkers that can signal mitochondrial dysfunction in heart failure. These markers help in early diagnosis and tracking the disease’s progression. Therapeutic Strategies: Potential treatments targeting mitochondrial dysfunction are discussed. These include mitochondrial-targeted antioxidants to reduce oxidative stress, drugs that promote mitochondrial health and biogenesis, and other approaches aimed at restoring normal mitochondrial function. mescreen™ can significantly enhance our understanding and management of heart failure by providing insights into the underlying cellular dysfunction. By evaluating mitochondrial parameters such as ATP production, reactive oxygen species (ROS) levels, and mitochondrial DNA integrity, clinicians can identify early signs of mitochondrial impairment and its impact on cardiac performance. These measurements help in diagnosing heart failure more accurately, monitoring disease progression, and tailoring targeted therapies aimed at improving mitochondrial health. mescreen.com 💜 #heartdisease #health #futureofmedicine #longevity

📈 Unveiling the Growth Trajectory The market for regenerative medicine is on a remarkable growth path, expanding from $4.24 billion in 2023 to $4.48 billion in 2024. Projections indicate it will reach $5.64 billion by 2028, reflecting a compound annual growth rate (CAGR) of 5.9%. 🔍 Understanding the Growth Drivers Sustained Rise in Chronic Diseases The increasing prevalence of chronic diseases, such as cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes, significantly drives market demand. These chronic conditions necessitate long-term solutions like regenerative medicine for cartilage repair and maintenance. 💡 Technological Advancements and Healthcare Expenditure The field of regenerative medicine is witnessing significant technological advancements, which are key drivers of market growth. Furthermore, increased healthcare spending is fostering robust research and development activities within this sector. For a deeper dive into these insights, refer to the Regenerative Medicine for Cartilage Market Report 2024. Stay tuned for more updates on the evolving landscape of regenerative medicine! https://lnkd.in/gfGDbhTF #RegenerativeMedicine #HealthcareInnovation #MarketGrowth #ChronicDiseases #TechAdvancements

Alzheimer disease (AD), as the leading cause of dementia and cognitive decline, requires innovative drug solutions addressing its multifaceted nature. To combat this complex disease, researchers explored various strategies, such as antioxidant mechanisms, promoting non-amyloidogenic pathways in amyloid precursor protein (APP) processing, inhibiting amyloid beta formation and polymerization, metal chelation, and cholinesterase inhibition. These diverse approaches aim to enhance AD’s neuro-protecting, cognitive-enhancing, and mood-modulating potential. Traditional medicine and pharmacy use plant secondary metabolites to mitigate AD side effects. Monoterpenes and diterpenes, characterized by their low molecular weight, exhibit valuable biological properties and clinical applications. Recent research has focused on their anti-AD properties. This study comprehensively reviews monoterpenes’ and diterpenes’ potential effects and mechanisms in addressing AD pathology. Additionally, clinical studies in this field are scrutinized, shedding light on the promising role of these secondary metabolites in managing AD. #AlzheimerDisease, #Diterpenes, #Monoterpenes, #Neurodegeneration

Fascinating insight from a recent study on Alzheimer’s diagnostics! 🧠 🔍 **Insights:** - Combined blood test for cognitive decline yields 90% accuracy in diagnosing Alzheimer’s 🩺 - Plasma phosphorylated tau 217 (p-tau217) test shows promise in detecting early Alzheimer’s indicators 🧬 - P-tau217 measures tau protein 217, a crucial marker for Alzheimer’s pathology 🔬 - Combination of p-tau217 and amyloid 42/40 ratio improves diagnostic accuracy 📊 - Potential game-changer for Alzheimer’s trials and medication development 💡 A groundbreaking advancement in Alzheimer’s detection, offering hope for earlier interventions and treatments. How might this impact the future of Alzheimer’s care? #AlzheimersResearch #MedicalAdvancements https://lnkd.in/duU8ukNK

#Diabetic #wounds, often resistant to conventional treatments, pose serious health risks to millions of people worldwide. #Immune cells known as #macrophages, which are supposed to help, end up causing #inflammation instead, making it harder for the wound to heal properly and quickly. Now, researchers from the Icahn School of Medicine at Mount Sinai and The Ohio State University have designed a #regenerative medicine therapy to speed up diabetic wound repair. Using #lipid #nanoparticles loaded with #RNA encoding a signaling protein known as a #cytokine, the therapy targeted dysfunctional macrophages while simultaneously reducing inflammation in diabetic wounds. "In preclinical models, we basically showed the therapy's ability to reprogram pro-inflammatory macrophages into reparative ones, leading to improved wound healing outcomes," said Yizhou Dong, one of the scientists involved in this study. https://lnkd.in/gqVgtuP6 (Work funded by The National Institutes of Health)